Comparison of single-pill strategies first line in hypertension: Perindopril/amlodipine versus valsartan/amlodipine

Journal of Hypertension

Volumn 33, Issue 5, 2015, Pages 1114-1116

  Kizilirmak, Pinar ^a   Ongen, Zeki ^b  

^a Novartis Pharma   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS PERINDOPRIL; AMLODIPINE PLUS VALSARTAN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; PERINDOPRIL;

ADVERSE OUTCOME; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG EXPOSURE; HUMAN; HYPERTENSION; LETTER; MONOTHERAPY; PRIORITY JOURNAL; STUDY DESIGN; FEMALE; MALE;

AMLODIPINE; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; MALE; PERINDOPRIL;

EID: 84929255976     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000544     Document Type: Letter

References (2)

1. Mancia G, Asmar R, Amodeo C, Mourad J-J, Taddei S, Gamba MAA, et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens 2015; 33:401-411.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised tripartite guideline: choice of control group and related issues in clinical trials: E10; step 4 version; 2000.